HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional)
NHLBI will fund a Clinical Trial Center and up to seven Clinical Centers to coordinate and conduct precision clinical trials for heart failure, focusing on patient recruitment, deep phenotyping, and personalized treatments.
Funder: National Institutes of Health
Due Dates: July 9, 2026 (Full application deadline)
Funding Amounts: Up to $500,000 per award; total program funding estimated at $3,465,000; up to 8 awards expected.
Summary: Supports Clinical Trial Center and Clinical Centers to advance precision clinical trials for heart failure with preserved ejection fraction (HFpEF) through the HeartShare 2.0 program.
Description
This funding opportunity solicits applications for a new Clinical Trial Center (CTC) and up to seven Clinical Centers (CCs) as part of the HeartShare 2.0 program, focused on heart failure with preserved ejection fraction (HFpEF). The CTC will lead and coordinate precision clinical trial activities, including protocol development, project management, recruitment oversight, performance milestones, and the scientific conduct of trials. Clinical Centers will focus on recruiting and retaining heart failure patients and controls, conducting deep phenotyping, longitudinal follow-up, obtaining tissue biopsies, and recruiting for future clinical trials. Applicants may propose either a CTC or CC, but must use different Principal Investigators (PIs) for each. Each application should clearly indicate whether it is for a CTC or CC in the project title.
